Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase IIb trial is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the use of Nitronezine tablets in the treatment of type II Efficacy and safety in subjects with subjects with mild to moderate diabetic nephropathy

Next Previous
X
Search
Trial Profile

A phase IIb trial is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the use of Nitronezine tablets in the treatment of type II Efficacy and safety in subjects with subjects with mild to moderate diabetic nephropathy

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Jul 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tetramethylpyrazine nitrone (Primary)
  • Indications Diabetic nephropathies
  • Focus Therapeutic Use
  • Sponsors Guangzhou Magpie Pharmaceuticals

    • Most Recent Events

    • 07 Jul 2021 According to Magpie media release, research was carried out in 16 centers across the country and is currently being successfully enrolled.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top